High Risk MDS to AML: Spring Virtual Conference | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

High Risk MDS to AML: Spring Virtual Conference

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presentation Date: 
Fri, 04/24/2020 - 8:00pm (EDT)

Daniel Pollyea, MD, MS, University of Colorado Health, gives a comprehensive overview of what happens when a higher risk MDS patient transitions to AML including the diagnositic criteria, treatment options and outcomes assessments. Dr. Pollyea also reviews some of the most promising treatment options that are in clinical trial and/or new to the treatment space. He also discusses the increasing success rates for older patients who go to transplant as a curative treatment for High Risk MDS and AML. Dr. Pollyea answers a number of patient-submitted questions as well.